Loading...
Market
Additional peer-reviewed studies on AAV9-based gene therapy for HSP50 by mid-2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Scientific journals and publication databases
Story
Gene Therapy Halts Progression of Rare Genetic Condition in 4-yr Old Toronto Boy Michael
Jun 28, 2024, 11:33 PM
A groundbreaking gene therapy has halted the progression of a rare genetic condition in a young boy from Toronto. The therapy, conducted at SickKids Hospital and published in Nature Medicine, involved a personalized AAV9-based gene therapy for hereditary spastic paraplegia type 50. The phase 1 trial, which included only one patient, showed that the therapy was well tolerated and led to preliminary disease stabilization within three years from diagnosis. The patient, Michael, a 4-yr old, is the son of Terry Pirovolakis, who played a significant role in making this treatment possible.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
Yes • 50%
No • 50%
Phase III trial initiation • 25%
FDA accelerated approval • 25%
New interim data release • 25%
Other milestone • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%
